Friday, October 15, 2021

The American Healthcare Industry Is More Evil Than Trump

God Is Hate: God Creates Disease and Suffering and The Medical ...:   A Review of Medical Errors in Laboratory Diagnostics and Where ...

A Review of Medical Errors in Laboratory Diagnostics and Where We Are Today

Laboratory Medicine, Volume 43, Issue 2, February 2012, Pages 41–44, https://doi.org/10.1309/LM6ER9WJR1IHQAUY
Published:
01 February 2012
Article history

Abstract

While many areas of health care are still struggling with the issue of patient safety, laboratory diagnostics has always been a forerunner in pursuing this issue. Significant progress has been made since the release of “To Err is Human.”1 This article briefly reviews laboratory quality assessment and looks at recent statistics concerning laboratory errors.

It has been 12 years since the Institute of Medicine (IOM) reported the alarming data on the cause and impact of medical errors in the United States.1 Besides causing serious harm to patients, medical errors translate into huge costs for the national economy. In 1999, Berwick and Leape published that the estimated cost of medical errors in the United States was between $17 billion-$29 billion a year.2 In 2006, Null and colleagues published an article indicating the overall estimated annual economic cost of improper medical intervention was much higher, approaching $282 billion.3 While many areas of health care are still struggling with the issue of patient safety, laboratory diagnostics has always been a forerunner in pursuing this issue. The concepts and practices of quality assessment programs have long been routine in laboratory medicine, and error rates in laboratory activities are far lower than those seen in overall clinical health care.4 This article briefly reviews laboratory quality assessment and looks at recent statistics concerning laboratory errors.

Quality Standards

Laboratory medicine sets high quality standards. Regulation of quality in the health care sector is based on accreditation, certification, quality monitoring, patient’s rights, standard operation processes, and standards of health care quality.5 The Centers for Medicare and Medicaid Services (CMS) regulates all laboratory testing (except research) performed on humans in the United States through the Clinical Laboratory Improvement Amendments (CLIA). The Division of Laboratory Services, within the Survey and Certification Group, under the Center for Medicaid and State Operations (CMSO), has the responsibility for implementing the CLIA program. The objective of the CLIA program is to ensure quality laboratory testing.6

In order for a health care organization to participate in and receive payment from Medicare or Medicaid programs, it must be certified as complying with the Conditions of Participation (CoP), or standards, set forth in federal regulations. This certification is based on a survey conducted by a state agency on behalf of CMS. However, if a national accrediting organization, such as The Joint Commission (TJC), formerly known as the Joint Commission on Accreditation of Health Care Organizations, has and enforces standards meeting the federal CoP, CMS may grant the accrediting organization “deeming” authority and “deem” each accredited health care organization as meeting the Medicare and Medicaid certification requirements. The health care organization is then considered to have “deemed status” and is not subject to the Medicare survey and certification process. Laboratories can also be accredited by the College of American Pathologists (CAP) and the Commission on Office Laboratory Accreditation (COLA), both of which also have deemed status with CMS.7,8,9

Sources of Laboratory Error

Traditionally, laboratory practice can be divided into 3 phases (pre-analytical, analytical, and post-analytical). All 3 phases of the total testing process can be targeted individually for improving quality, although it is well published that most errors occur in the pre- and post-analytical phases (Table 1).10 In the field of laboratory medicine, Lippi and colleagues published that the total testing process error rate ranges widely from 0.1% to 3.0%.11 In studies done by Plebani and Carraro, laboratory error rates declined over 10 years from 0.47% in 1977 to 0.33% in 2007.12,13 A similar declining trend has been seen specifically in analytical errors. The analytical variability is now frequently less than 1/20th of what it was 40 years ago.14 Analytical mistakes now count for <10% of all mistakes.12

Analytical Error

Focusing first on the analytical phase of laboratory testing, the analytical phase begins when the patient specimen is prepared in the laboratory for testing, and it ends when the test result is interpreted and verified by the technologist in the laboratory. Not processing a specimen properly prior to analysis or substances interfering with assay performance can affect test results in the analytical phase. Establishing and verifying test method performance specifications as to test accuracy, precision, sensitivity, specificity, and linearity are other areas where errors can occur in the analytical phase of laboratory testing.

The laboratory has spent decades improving analytical quality by establishing internal quality controls (IQC) and external quality assessment (EQA). The role of EQA and proficiency testing (PT) is to provide reliable information allowing laboratories to assess and monitor the quality status of internal procedures and processes, the suitability of the diagnostic systems, the accountability and competence of the staff, along with the definition of measurement uncertainty in laboratory results. The responsibility of laboratory professionals is to appropriately analyze EQA/PT samples and reports, detect trends or bias that may not be apparent in single results, investigate root causes producing unacceptable performances, apply and monitor opportune actions for removing the underlying cause(s), verify the effectiveness, and, above all, determine whether the problem affected clinical decision making.15

Pre-analytical Error

The pre-analytical phase of the total laboratory testing process is where the majority of laboratory errors occur. Pre-analytical errors can occur at the time of patient assessment, test order entry, request completion, patient identification, specimen collection, specimen transport, or specimen receipt in the laboratory. A report by Bonini and colleagues found that pre-analytical errors predominated in the laboratory, ranging from 31.6% to 75%.16In 2008 to 2009, Chawla and colleagues performed a 1-year study in the clinical chemistry laboratory on the frequency of pre-analytical errors observed in both inpatients and outpatients. For the inpatients, a pre-analytical error rate of 1.9% was reported. The variable receiving the highest frequency rating was specimen hemolysis at 1.10%. For the outpatients, the error rate was 1.2%, and the variable with the highest frequency rating was insufficient volume for testing.17 Some of the other common sources of pre-analytical error are the following: ordering tests on the wrong patient, ordering the wrong test, misidentifying the patient, choosing the inappropriate collection container, or labeling containers improperly.

A comprehensive plan to prevent pre-analytical errors has 5 interrelated steps:

  1. Developing clear written procedures.

  2. Enhancing health care professional training.

  3. Automating functions, both for support operations and for executive operations.

  4. Monitoring quality indicators.

  5. Improving communication among health care professionals and fostering interdepartmental cooperation.18,19,20


























Table 1

Types and Rates of Error in the 3 Stages of the Laboratory Testing Process9,20

Phase of Total Testing ProcessType of ErrorRates
Pre-analytical Inappropriate test request 46%–68.2% 
Order entry errors 
Misidentification of patient 
Container inappropriate 
Sample collection and transport inadequate 
Inadequate sample/anticoagulant volume ratio 
Insufficient sample volume 
Sorting and routing errors 
Labeling errors 
Analytical Equipment malfunction 7%–13% 
Sample mix-ups/interference 
Undetected failure in quality control 
Procedure not followed 
Post-analytical Failure in reporting 18.5%–47% 
Erroneous validation of analytical data 
Improper data entry 

Written procedures must clearly explain how to identify a patient, collect and label a specimen, and subsequently transport the specimen and prepare it for analysis. Those individuals performing the pre-analytical procedures must understand not only what the procedures are but why they are important to follow. They need to know not only what happens if the correct steps are not followed, but also what errors can occur and what effect they can have on the sample and ultimately the patient. There must be ongoing training for these employees and competencies must be assessed annually.21

Modern robotic technologies and information systems can also help reduce pre-analytical errors. Computerized order entry simplifies test ordering and eliminates a second person from transcribing the orders. Automated phlebotomy tray preparation provides a complete set of labeled blood tubes and labels for hand labeling in a single tray for each patient. Pre-analytical robotic workstations automate some of the steps and reduce the number of manual steps involving more people. Barcodes also simplify specimen routing and tracking.21

Recent advances in laboratory technology have made available new and more reliable means for the automated detection of the serum indices, including the hemolysis index. Visual detection of hemolysis must be abandoned due to low sensitivity and low reproducibility. Laboratory personnel must ask for new samples when hemolysis is detected. If a new sample cannot be obtained, it is the responsibility of the laboratory specialist to communicate the problem to the clinician. The data obtained from the serum indices can be used to monitor the quality of the collection process.22

Post-analytical Error

In the post-analytical phase of the testing process, results are released to the clinician, and s/he interprets them and makes diagnostic and therapeutic decisions accordingly. Such things as inappropriate use of laboratory test results, critical result reporting, and transmission of correct results are areas of potential error in the post-analytical phase of the total laboratory testing process.

In an article by Plebani and Piva, the authors give a comprehensive overview on the ongoing efforts for improving actual consensus on the definition and notification of laboratory critical values, and for evaluating their contribution to improve clinical outcomes and patient safety. The article also provides some highlights on a valuable experience of automated notification, which is a reliable tool for improving the timeliness of communication and avoiding potential errors for which accreditation programs require read-back of the results.23

Monitoring Errors

The success of any efforts made to reduce errors must be monitored in order to assess the efficacy of the measures taken. Quality indicators must be used for assessment. In the testing process areas involving non-laboratory personnel, interdepartmental communication and cooperation are crucial to avoid errors. Therefore the entire health care system must be involved in improving the total testing process. There must be adequate and effective training of personnel throughout the institution to be competent in following processes and procedures.21

Incident Reporting in Laboratory Diagnostics

While major efforts have been made to monitor the pre-analytical phase and provide reliable solutions, it is surprising that concrete formal programs of incident reporting have not been so pervasive in laboratory diagnostics.24 The major focus in health care is placed on incident reporting for several medical conditions with lesser effort devoted to translating this noteworthy practice into laboratory diagnostics. If, in fact, laboratory errors are being underreported, then current statistics reveal only a small portion of the medical errors actually taking place. There is an urgent need to establish a reliable policy of error recording, possibly through informatics aids,25 and settle universally agreed “laboratory sentinel events” throughout the total testing process, which would allow gaining important information about serious incidents and holding both providers and stakeholders accountable for patient safety. Some of these sentinel events have already been identified, including inappropriate test requests and patient misidentification (pre-analytical phase), use of wrong assays, severe analytical errors, tests performed on unsuitable samples, release of lab results in spite of poor quality controls (analytical phase), and failure to alert critical values and wrong report destination (post-analytical phase).26,27 The Drafting Group of WHO’s International Classification for Patient Safety (ICPS) has also developed a conceptual framework that might also be suitable for diagnostics errors.28

Development and widespread implementation of a Total Quality Management (TQM) system is the most effective strategy to minimize uncertainty in laboratory diagnostics. Pragmatically, this can be achieved using 3 complementary actions: preventing adverse events (error prevention), making them visible (error detection), and mitigating their adverse consequences when they occur (error management).24

Other methodologies can also be used to prevent errors. Failure Mode and Effect Analysis (FMEA) has been a broadly cited reliable approach to risk management. It is a systematic process for identifying potential process failures before they occur, with the aim to eliminate them or minimize the relative risk. The U.S. Department of Veteran Affairs National Center for Patient Safety developed a simplified version of FMEA to apply to health care, called Healthcare FMEA (HFMEA).29 Root Cause Analysis (RCA) is an additional valuable aid, since it is based on a retrospective analytical approach. A RCA focuses on identifying the latent conditions underlying variation in medical performance and, if applicable, developing recommendations for improvements to decrease the likelihood of a similar incident in the future.11

Conclusion

Patient safety emphasizes the reporting, analysis, and prevention of medical errors that often lead to adverse events. Besides carrying serious harms to patient health, medical errors translate into a huge amount of money wiped out of the national and international economy. Significant progress has been made since the release of “To Err is Human.” Basically what has changed is the willingness to recognize the challenge and not argue about the numbers, but appreciate care must be safe always and everywhere for each patient. This has led to remarkable changes in the culture of health care organizations, so medical errors can no longer be seen as inevitable, but as something that can be actively streamlined and prevented.24

Monday, October 4, 2021

How to fund the infra-structure bill

 






How The Filthy Rich Criminal Elite Hide Their Ill-Gotten Wealth



Russian President Vladimir Putin's inner circle shuffled as much as $US2 billion ($2.7 billion) through shadow companies using a network of law firms and banks that helps billionaires, celebrities, politicians, fraudsters and drug traffickers hide their wealth, confidential documents show.


One of the biggest leaks of confidential financial information in history, obtained in a global investigation by media organisations including The Australian Financial Review, reveals the inside workings of a shadowy financial system that allows the wealthy and powerful to shift capital around the world where governments and tax agencies can't find it.

The 11.5 million files expose offshore companies controlled by the prime ministers of Iceland and Pakistan, the king of Saudi Arabia and the children of the President of Azerbaijan. They include at least 33 people and companies blacklisted by the US government because of evidence that they've done business with Mexican drug lords, terrorist organisations like Hezbollah or rogue nations like North Korea and Iran.

Russian President Vladimir Putin's associates made an appearance in Panama Papers. AP

The leaked records come from an obscure law firm based in Panama, Mossack Fonseca, one of the world's top creators of shell companies, corporate structures that can be used to hide ownership of assets. The documents were investigated by the International Consortium of Investigative Journalists, German newspaper Süddeutsche Zeitung and more than 100 other news organisations, including the Financial Review.

The documents reveal major banks are big drivers behind the creation of hard-to-trace companies in the British Virgin Islands, Panama and other tax havens. The files list more than 15,600 paper companies that banks set up for clients who want to keep their finances under wraps, including thousands created by international banks UBS and HSBC.


Most of the services the offshore industry provides are legal if used by the law-abiding. But the documents show that banks, law firms and other offshore players often failed to follow legal requirements that they make sure their clients are not involved in criminal enterprises, tax dodging or political corruption. In some instances, the files show, offshore middlemen have protected themselves and their clients by concealing suspect transactions or manipulating official records.

"These findings show how deeply ingrained harmful practices and criminality are in the offshore world," said Gabriel Zucman, an economist at the University of California at Berkeley and author of The Hidden Wealth of Nations: The Scourge of Tax Havens.

Zucman said the release of the leaked documents should prompt governments to seek "concrete sanctions" against countries and institutions that peddle offshore secrecy.

The records reveal a pattern of covert manoeuvres by banks, companies and people tied to the Russian president. The records show offshore companies linked to this network moving money in transactions as large as $US200 million ($260.8 million) at a time. Putin associates disguised payments, backdated documents and gained hidden influence within the country's media and automotive industries, the leaked files show.

The Mossack Fonseca building in Panama.

A Kremlin spokesman did not answer questions for this story, but instead went public March 28 with charges that ICIJ and its media partners were preparing a misleading "information attack" on Putin and people close to him

World leaders who have embraced anti-corruption platforms feature in the leaked documents. The files reveal offshore companies linked to the family of China's top leader, Xi Jinping, who has vowed to fight "armies of corruption", as well as Ukrainian President Petro Poroshenko, who has positioned himself as a reformer in a country shaken by corruption scandals. The files also contain new details of offshore dealings by the late father of British Prime Minister David Cameron, a leader in the push for tax-haven reform.

The leaked data covers nearly 40 years, from 1977 through to the end of 2015. It allows a never-before-seen view inside the offshore world — providing a day-to-day, decade-by-decade look at how dark money flows through the global financial system, breeding crime and stripping national treasuries of tax revenues.

The data includes emails, financial spreadsheets, passports and corporate records revealing the secret owners of bank accounts and companies in 21 offshore jurisdictions, from Nevada to Singapore to the British Virgin Islands.

An unprecedented investigation into more than 9 million secret files has exposed the hidden underground of the world economy, a network of banks, law firms and other middlemen that hides extraordinary – and often illegal – wealth. Reuters

In Iceland, the leaked files show how Prime Minister Sigmundur David Gunnlaugsson and his wife secretly owned an offshore firm that held millions of dollars in Icelandic bank bonds during that country's financial crisis.
Criminal connections

The files include a convicted money launderer who claimed he had arranged a $50,000 illegal campaign contribution used to pay the Watergate burglars, 29 billionaires featured in Forbes Magazine's list of the world's 500 richest people, and movie star Jackie Chan, who has at least six companies managed through the law firm.

As with many of Mossack Fonseca's clients, there is no evidence that Chan used his companies for improper purposes. Having an offshore company isn't illegal. For some international business transactions, it's a logical choice.

The Mossack Fonseca documents indicate, however, that the firm's customers have included Ponzi schemers, drug kingpins, tax evaders and at least one jailed sex offender. A US businessman convicted of travelling to Russia to have sex with underage orphans signed papers for an offshore company while he was serving his prison sentence in New Jersey, the records show.


The files contain new details about major scandals ranging from England's most infamous gold heist to the bribery allegations convulsing FIFA, the body that rules international soccer.

The leaked documents reveal that the law firm of Juan Pedro Damiani, a member of FIFA's ethics committee, had business relationships with three men who have been indicted in the FIFA scandal – former FIFA vice-president Eugenio Figueredo and Hugo and Mariano Jinkis, the father-son team accused of paying bribes to win broadcast rights to Latin American soccer events. The records show that Damiani's law firm in Uruguay represented an offshore company linked to the Jinkises and seven companies linked to Figueredo.

In response to the reporting by ICIJ and its media partners, FIFA's ethics panel has launched a preliminary investigation into Damiani's relationship to Figueredo. A spokesman for the committee said Damiani first informed the panel about his business ties to Figueredo on March 18. That was one day after the reporting team sent questions to Damiani about his law firm's work for companies tied to the former FIFA vice president.

The world's top soccer player, Lionel Messi, is named.The records show Messi and his father were owners of a Panama company, Mega Star Enterprises Inc. His offshore dealings are currently the target of a tax evasion case in Spain.


Mossack Fonseca's fingers are in Africa's diamond trade, the international art market and other businesses that thrive on secrecy. The firm has serviced enough Middle East royalty to fill a palace. It's helped two kings, Mohammed VI of Morocco and King Salman of Saudi Arabia, take to the sea on luxury yachts. The law firm's leaked internal files contain information on 214,488 offshore entities connected to people in more than 200 countries and territories.

Whether they're famous or unknown, Mossack Fonseca works aggressively to protect its clients' secrets. In Nevada, the records show, the law firm tried to shield itself and its clients from the fallout from a legal action in US District Court by removing paper records from its Las Vegas branch and having its tech gurus wipe electronic records from phones and computers.

The leaked files show the firm regularly offered to backdate documents to help its clients gain advantage in their financial affairs. It was so common that in 2007 an email exchange shows firm employees talking about establishing a price structure – clients would pay $US8.75 for each month farther back in time that a corporate document would be backdated.

In a written response to questions, the law firm said it "does not foster or promote illegal acts. Your allegations that we provide shareholders with structures supposedly designed to hide the identity of the real owners are completely unsupported and false."

Backdating of documents "is a well-founded and accepted practice" that is "common in our industry and its aim is not to cover up or hide unlawful acts", it said.

The firm said it couldn't answer questions about specific customers because of its obligation to maintain client confidentiality.

The law firm's co-founder, Ramón Fonseca, told Panamanian television that the firm was like a "car factory" whose liability ends once the car is produced. Blaming Mossack Fonseca for what people do with their companies would be like blaming a car maker "if the car was used in a robbery", he said.

The International Consortium of Investigative Journalists will release the full list of companies and people linked to the firm in early May.

The sleek and non-transparent Mossack Fonseca building in Panama City.

Until recently, Mossack Fonseca has largely operated in the shadows. But it has come under growing scrutiny as governments have obtained partial leaks of the firm's files and authorities in Germany and Brazil began probing its practices.

In February 2015, Süddeutsche Zeitung reported that German law-enforcement agencies had launched a series of raids targeting one of the country's biggest banks, Commerzbank, in a tax-fraud investigation that authorities said could lead to criminal charges against Mossack Fonseca employees.

In Brazil, the law firm has become a target in a bribery and money laundering investigation dubbed "Operation Car Wash" ("Lava Jato," in Portuguese), which has led to criminal charges against leading politicians and an investigation of popular former president Luiz Inacio Lula da Silva. The scandal threatens to unseat current President Dilma Rousseff.

In January, Brazilian prosecutors labelled Mossack Fonseca as a "big money launderer" and announced they had filed criminal charges against five employees of the firm's Brazilian office for their role in the scandal.

Mossack Fonseca denies any wrongdoing in Brazil.

The disclosures found inside the law firm's leaked files dramatically expand on previous leaks of offshore records that ICIJ and its reporting partners have revealed in the past four years.

In the largest media collaboration ever undertaken, journalists working in more than 25 languages dug into Mossack Fonseca's inner workings and traced the secret dealings of the law firm's customers around the world. They shared information and hunted down leads generated by the leaked files using corporate filings, property records, financial disclosures, court documents and interviews with money laundering experts and law-enforcement officials.

Reporters at Süddeutsche Zeitung obtained millions of records from a confidential source and shared them with ICIJ and other media outlets. . The news outlets involved in the collaboration did not pay for the documents.

Before Süddeutsche Zeitung obtained the leak, German tax authorities bought a smaller set of Mossack Fonseca documents from a whistleblower, a move that triggered the raids in Germany in early 2015. This smaller set of files has since been offered to tax authorities in the United Kingdom, the United States and other countries, according to sources with knowledge of the matter.

The larger set of files obtained by the news organisations offers more than a snapshot of one law firm's business methods or a catalog of its more unsavory customers. It allows a far-reaching view into an industry that has worked to keep its practices hidden – and offers clues as to why efforts to reform the system have faltered.

The story of Mossack Fonseca is, in many ways, the story of the offshore system itself.
Crime of the Century

Before dawn on Nov. 26, 1983, six robbers slipped into the Brink's-Mat warehouse at London's Heathrow Airport. The thugs tied up the security guards, doused them in gasoline, lit a match and threatened to set them afire unless they opened the warehouse's vault. Inside, the thieves found nearly 7000 gold bars, diamonds and cash.

"Thanks ever so much for your help. Have a nice Christmas," one of the crooks said as they departed.

British media dubbed the heist the "Crime of the Century." Much of the loot – including the cash reaped by melting the gold and selling it – was never recovered.

Where the missing money went is a mystery that continues to fascinate students of England's underworld.

Mossack Fonseca's files reveal that the law firm and its co-founder, Jürgen Mossack, may have helped the conspirators keep the spoils out of the hands of authoritiesby protecting a company tied to Gordon Parry, a London wheeler-dealer who laundered money for the Brink's-Mat plotters.

Sixteen months after the robbery, the records show, Mossack Fonseca set up a Panama shell company called Feberion for Gordon Parry, a London wheeler-dealer who laundered money for the Brink's-Mat plotters. Jürgen Mossack was listed as one the company's three "nominee" directors, a term used in the business for stand-ins who control a company on paper but exercise no real authority over its activities.

An internal memo written by Mossack shows he was aware in 1986 that the company was "apparently involved in the management of money from the famous theft from Brink's-Mat in London. The company itself has not been used illegally, but it could be that the company invested money through bank accounts and properties that was illegitimately sourced".

Mossack Fonseca records from 1987 make it clear that Parry was behind Feberion.

After police obtained the two certificates that controlled the company's ownership, Mossack Fonseca arranged for Feberion to issue 98 new shares, a move that appears to have effectively wrested control away from investigators, the leaked records show.

It was not until 1995 – three years after Parry was sentenced to a decade in prison for his role in the theft – that Mossack Fonseca ended its business relationship with Feberion.

A spokesman for the law firm said any allegations the firm helped shield the proceeds of the Brink's-Mat robbery "are entirely false." The spokesman said Jürgen Mossack "never had any dealings" with Parry and was never contacted by police about the case.

In its efforts to protect Feberion, the shell company linked to the Brink's-Mat gold heist, Mossack Fonseca used the services of a Panama-based firm, Chartered Management Company, run by Gilbert R.J. Straub, an American expatriate who played a cameo role in the Watergate scandal.

In 1987, as UK police were investigating the shell company, Jürgen Mossack and Fiberion's other on-paper directors resigned, with the understanding they would be replaced by new directors appointed by Straub's Chartered Management, the secret files show.

Straub was eventually caught in a US Drug Enforcement Administration sting that was unrelated to the Brink's-Mat case, according to Mazur, the former undercover agent. Mazur built the case that led Straub to plead guilty to money laundering in 1995. During Mazur's deep-cover stint, Mazur said, Straub tried to establish his criminal bona fides by describing how he'd illegally chaneled cash to President Nixon's 1972 re-election campaign.
Protecting clients

Mossack Fonseca's defence of the dodgy company illustrates how far many offshore operatives will go to serve their customers' interests.

The offshore system relies on a sprawling global industry of bankers, lawyers, accountants and other middlemen who work together to protect their clients' secrets. These secrecy experts use anonymous companies, trusts and other paper entities to create complex structures that can be used to disguise the origins of dirty money.

"They are the gasoline that runs the engine," said Robert Mazur, a former US drug agent and author of The Infiltrator: My Secret Life Inside the Dirty Banks Behind Pablo Escobar's Medellín Cartel. "They're an extraordinarily important piece of the formula of success for criminal organisations."

Mossack Fonseca told ICIJ that it follows "both the letter and spirit of the law. Because we do, we have not once in nearly 40 years of operation been charged with criminal wrongdoing."

The men who founded the firm decades ago – and continue today as its main partners – are well-known figures in Panamanian society and politics.

Jürgen Mossack is a German immigrant whose father sought a new life in Panama for his family after serving in Hitler's Waffen-SS during World War II. Ramón Fonseca is an award-winning novelist who has worked in recent years as an adviser to Panama's president. He took a leave of absence as a presidential adviser in March after his firm was implicated in the Brazil scandal and ICIJ and its partners began to ask questions about the firm's practices.

From its base in Panama, one of the world's top financial secrecy zones, Mossack Fonseca seeds anonymous companies in Panama, the British Virgin Islands and other financial havens.

The law firm has worked closely with big banks and big law firms in places like The Netherlands , Mexico, the United States and Switzerland, helping clients move money or slash their tax bills, the secret records show.

An ICIJ analysis of the leaked files found that more than 500 banks, their subsidiaries and branches worked with Mossack Fonseca since the early 1990s to help clients use offshore companies. UBS set up more than 1100 offshore companies through Mossack Fonseca. HSBC and its affiliates created more than 2300.

In all, the files indicate Mossack Fonseca worked with more than 14,000 banks, law firms, company incorporators and other middlemen to set up companies, foundations and trusts for customers, the records show.

Mossack Fonseca says these middlemen are its true clients, not the eventual customers who use offshore companies. The firm says these middlemen provide additional layers of oversight for reviewing new customers. As for its own procedures, Mossack Fonseca says they often exceed "the existing rules and standards to which we and others are bound."
Reforming the secret world

In 2013, British Prime Minister David Cameron urged his country's overseas territories – including the British Virgin Islands – to "get our own houses in order" and join the fight against tax evasion and offshore secrecy. He could have looked no further than his late father to see how challenging that would be.

Ian Cameron, a stockbroker and multimillionaire, was a Mossack Fonseca client who used the law firm to shield his investment fund, Blairmore Holdings, from British taxes.

The fund's name came from Blairmore House, his family's ancestral country estate. Mossack Fonseca registered the investment fund in Panama even though many of its key investors were British. Ian Cameron controlled the fund from its birth in 1982 until his death in 2010.

A prospectus for investors said the fund "should be managed and conducted so that it does not become resident in the United Kingdom for United Kingdom taxation purposes".

The fund did this by using untraceable certificates of ownership known as "bearer shares" and by employing "nominee" company officers based in the Bahamas, the law firm's leaked records show.

Ian Cameron's tax-haven history is an example of how deeply offshore secrecy is woven into the lives of political and financial elites around the world. It's also an important economic engine for many countries. The weight of that self-interest has made reform difficult.

In the US, for example, states like Delaware and Nevada, which have allowed company owners to remain anonymous, continue to fight against efforts to require greater corporate transparency.

Mossack Fonseca's home country, Panama, has refused to embrace a plan for worldwide exchange of information about bank accounts – out of concern that its offshore industry could be left at a disadvantage. Panama officials say they will exchange information, but on a more modest scale.

The challenge that reformers and law enforcers face is how to find and stop criminal behaviour when it's buried beneath layers of secrecy. The most effective tool for breaking through this secrecy has been leaks of offshore documents that have dragged hidden dealings into the open.

Document leaks uncovered by ICIJ and its media partners have prompted legislation and official investigations in dozens of countries – and fanned fears among offshore customers who worry their secrets will be revealed.

In April 2013, after ICIJ released its "Offshore Leaks" stories based on confidential documents from the British Virgin Islands and Singapore, some Mossack Fonseca customers emailed the firm looking for reassurance that their offshore holdings were safe from scrutiny.

Mossack Fonseca told customers not to worry. It said its commitment to its clients' privacy "has always been paramount, and in this regard your confidential information is stored in our state-of-the-art data centre, and any communication within our global network is handled through an encryption algorithm that complies with the highest world-class standards".

The Panama Papers - Read more:
Tax Office targets 800 Australians in global tax haven probe
NZ - the quiet tax haven achiever
ANZ was the leading Australian bank in Mossack's universe
Secrets of Mossack Fonseca & Co
How the one per centers divorce
Records reveal money network tied to Putin
Leak ties ethics guru to three men charged in FIFA scandal

Part 1: How The Filthy Rich Hide Their Ill-Gotten Wealth

 Everybody knows what a “Swiss bank account” is. Hollywood tells us they’re top-secret safety deposit boxes for the world’s elite — places where drug kingpins and bankers and politicians and heirs hide their fortunes from government investigations and taxation. They’re how the super rich do banking.

Now, thanks to one whistleblower and a team of 140 journalists from around the world, we know a lot more about these accounts and the people who hold them.

We know more about how Swiss banking has helped the richest people in the world to accumulate and protect their every growing share of the world’s total wealth. We know how banks have helped drug traffickers, arms dealers, and terrorists to launder money and create financial infrastructures that have made them less like criminal gangs operating in dirty cash and more like global criminal enterprises earning interest, making investments, and sending wire transfers. And we know more about how corrupt governments, government officials, and political leaders have embezzled money and robbed the people they’re meant to serve.

Here’s how we know all this.

In 2009, Hervé Falciani, an IT worker at the British bank HSBC leaked information to French tax investigators that showed HSBC had been stashing clients’ funds in its Swiss subsidiary, HSBC Private Bank. French newspaper Le Monde got ahold of the information in 2014 and set up a collaboration with the the Washington DC-based International Consortium of Investigative Journalists (ICIJ). The new partners recruited a team of investigative journalists from over 45 countries to mine the data, which relates to over 100,000 banking clients in 200 countries, and find the stories.

On Feb. 8, the ICIJ launched its interactive report: “Swiss Leaks.”


“Swiss Leaks” has three main sections: Countries, People, and Stories. Each does something different, and each is deeply troubling in its own way.

 

Countries

“Countries” gives you the meta-level picture of where the money was coming from — how much money from each country and how many banking clients per country. (You can see that information in graphic form throughout this article.)

People

The “People” section of the report includes profiles of 65 public figures connected to HSBC Swiss accounts. (It’s a sample of the larger data. In its written report, ICIJ discusses many other people.)

You’ll learn, for example, that Mexican billionaire Carlos Hank Rohn was the beneficial owner of 10 bank accounts listed to “Hmex Pte. Ltd” that held a total of around $158 million in 2006/2007.

You’ll also learn that King of Jordan, Abdullah II ibn al-Hussein, was connected to an account opened in the name of a person ICIJ identifies as a “senior palace official.” It held $41.8 billion in 2006/2007.  

And there’s plenty more info on arms traffickers, diamond dealers, politicians, sports figures, corporate executives, and celebrities — a pretty diverse crew of people who share one thing in common. They are super rich.



Read “People” carefully, though. Not every person with an HSBC Swiss account is evading taxes and laundering money, as ICIJ notes. Several people responded to ICIJ’s request for comment with compelling explanations.

Take British musician Phil Collins. He’s listed. Bad look, right? Not when you ask Collins’ manager, who explained to ICIJ that the singer actually lives in Switzerland and that “It is entirely appropriate for him to have a bank account where he lives.”

Another example: Australian supermodel Elle Macpherson. She’s been the beneficial owner of several client accounts linked to over two dozen bank accounts. In 2006/2007 those accounts held $12.2 million. Tax dodger? Maybe not. “Ms. MacPherson is an Australian citizen,” her lawyers told ICIJ, and she has “accounted for UK tax on the basis of full disclosure in accordance with UK law.”

One lesson from Swiss Leaks is that each HSBC account is a story worth investigating.

 


Sunday, October 3, 2021

FDA: More Evil Than Trump More Deadly Than War

 

Risky Drugs: Why The FDA Cannot Be Trusted

by Donald W. Light

forthcoming article for the special issue of the Journal of Law, Medicine and Ethics (JLME), edited by Marc Rodwin and supported by the Edmond J. Safra Center for Ethics, presents evidence that about 90 percent of all new drugs approved by the FDA over the past 30 years are little or no more effective for patients than existing drugs.

All of them may be better than indirect measures or placebos, but most are no better for patients than previous drugs approved as better against these measures. The few superior drugs make important contributions to the growing medicine chest of effective drugs.

The bar for “safe” is equally low, and over the past 30 years, approved drugs have caused an epidemic of harmful side effects, even when properly prescribed. Every week, about 53,000 excess hospitalizations and about 2400 excess deaths occur in the United States among people taking properly prescribed drugs to be healthier. One in every five drugs approved ends up causing serious harm,1 while one in ten provide substantial benefit compared to existing, established drugs. This is the opposite of what people want or expect from the FDA.

Prescription drugs are the 4th leading cause of death. Deaths and hospitalizations from over-dosing, errors, or recreational drug use would increase this total. American patients also suffer from about 80 million mild side effects a year, such as aches and pains, digestive discomforts, sleepiness or mild dizziness.

The forthcoming article in JLME also presents systematic, quantitative evidence that since the industry started making large contributions to the FDA for reviewing its drugs, as it makes large contributions to Congressmen who have promoted this substitution for publicly funded regulation, the FDA has sped up the review process with the result that drugs approved are significantly more likely to cause serious harm, hospitalizations, and deaths. New FDA policies are likely to increase the epidemic of harms. This will increase costs for insurers but increase revenues for providers.

This evidence indicates why we can no longer trust the FDA to carry out its historic mission to protect the public from harmful and ineffective drugs. Strong public demand that government “do something” about periodic drug disasters has played a central role in developing the FDA.2 Yet close, constant contact by companies with FDA staff and officials has contributed to vague, minimal criteria of what “safe” and “effective” mean. The FDA routinely approves scores of new minor variations each year, with minimal evidence about risks of harm. Then very effective mass marketing takes over, and the FDA devotes only a small percent of its budget to protect physicians or patients from receiving biased or untruthful information.34 The further corruption of medical knowledge through company-funded teams that craft the published literature to overstate benefits and understate harms, unmonitored by the FDA, leaves good physicians with corrupted knowledge.5 6 Patients are the innocent victims.

Although it now embraces the industry rhetoric about “breakthrough” and “life-saving” innovation, the FDA in effect serves as the re-generator of patent-protected high prices for minor drugs in each disease group, as their therapeutic equivalents lose patent protection. The billions spent on promoting them results in the Inverse Benefit Law: the more widely most drugs are marketed, the more diluted become their benefits but more widespread become their risks of harm.

The FDA also legitimates industry efforts to lower and widen criteria prescribing drugs, known by critics as “the selling of sickness.” Regulations conveniently prohibit the FDA from comparing the effectiveness of new drugs or from assessing their cost-effectiveness. Only the United States allows companies to charge what they like and raise prices annually on last year’s drugs, without regard to their added value.7

A New Era?

Now the FDA is going even further. The New England Journal of Medicine has published, without comment, proposals by two senior figures from the FDA to loosen criteria drugs that allege to prevent Alzheimer’s disease by treating it at an early stage.8 The authors seem unaware of how their views about Alzheimer’s and the role of the FDA incorporate the language and rationale of marketing executives for the industry. First, they use the word “disease” to refer to a hypothetical “early-stage Alzheimer’s disease” that supposedly exists “before the earliest symptoms of Alzheimer’s disease are apparent.” Notice that phrasing assumes that the earliest symptoms will become apparent, when in fact it’s only a hypothetical model for claiming that cognitive lapses like not remembering where you put something or what you were going to say are signs of incipient Altzheimer’s disease. The proposed looser criteria would legitimate drugs as “safe and effective” that have little or no evidence of being effective and expose millions to risks of harmful side effects.

No proven biomarkers or clinical symptoms exist, the FDA officials note, but nevertheless they advocate accelerated approval to allow “drugs that address an unmet medical need.” What “unmet need"? None exists. This market-making language by officials who are charged with protecting the public from unsafe drugs moves us towards the 19-century hucksterism of peddling cures of questionable benefits and hidden risks of harm, only now fully certified by the modern FDA.9

The main reason for advocating approvals of drugs for an unproven need with unproven benefits, these FDA officials explain, is that companies cannot find effective drugs for overt Alzheimer’s. Their drug-candidates have failed again and again in trials. The core rationale of the proposed loosening of criteria is that “the focus of drug development has sifted to earlier stages of Alzheimer’s disease…and the regulatory framework under which such therapies are evaluated should evolve accordingly.” Yet they admit there are no “therapies” in this much larger market where (with the help of the industry-funded FDA) companies will not have to prove their drugs are effective. In fact, these FDA officers propose to approve the drugs without ever knowing if they are therapeutic or not. Their commercialized language presumes the outcome before starting. The job of the FDA, it seems, is to help drug companies open up new markets to increase profits for the FDA’s corporate paymasters.

These two FDA officials maintain that “the range of focus must extend to healthy people who are merely at risk for the disease but could benefit from preventive therapies.” Yet they admit we do not know who is “at risk,” nor whether there is a “disease,” nor whether anyone “could benefit,” nor whether the drugs constitute “preventive therapies.” Similar FDA-encouraged shifts have been made for drugs treating pre-diabetes, pre-psychosis, and pre-bone density loss, with few or no benefits to offset risks of harm. This week, based on policy research at the Edmond J. Safra Center for Ethics, a letter of concern was published in the New England Journal of Medicine. The authors write that approval for drugs to treat “early stage Altzheimer’s disease” must meet “a much higher bar – evidence of slowed disease progression.” But without clinical manifestations or biomarkers for an alleged disease, how will such progression be measured?

Advice to readers: Experienced, independent physicians recommend not to take a new drug approved by the FDA until it is out for 7 years, unless you have to, so that evidence can accumulate about its real harms and benefits.10

----

Disclaimer: The assessment and views expressed here are solely the author’s and do not necessarily reflect those of persons or institutions to which he is associated. The comments and suggestions of Gordon Schiff, an expert in prescribing at Brigham and Women’s Hospital, and Robert Whitaker are gratefully acknowledged.

References

1. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Archives of Internal Medicine 2012 (Nov 26);172:1680-81.

2. Hilts PJ. Protecting America's Health: The FDA, Business and One Hundred Years of Regulation. New York: Alfred A. Knopf; 2003.

3. Rodwin M. Conflicts of interest, institutional corruption, and Pharma: an agenda for reform. Journal of Law, Medicine & Ethics 2012;40:511-22.

4. Rodwin M. Reforming pharmaceutical industry-physician financial relationships: lessons from the United States, France, and Japan. Journal of Law, Medicine & Ethics 2011(Winter):2-10.

5. Sismondo S. Ghost management. PLoS Medicine 2007;4:1429-33.

6. Sismondo S, Doucet M. Publication ethics and the ghost management of medical publication. Bioethics 2010;24:273-83.

7. Schondelmeyer S, Purvis L. Rx Price Watch Report. Washington DC: American Association of Retired Persons 2012.

8. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. New England Journal of Medicine 2013 (Mar 13);DOI: 10.1056/NEJMp1302513

9. Young JH. The Toadstool Millionaires: a social history of patent medicines in America before federal regulation. Princeton, NJ: Princeton University Press; 1961.

10. Schiff G, Galanter W, Duhig J, et al. Principles of conservative prescribing. Archives of Internal Medicine 2011;171:1433-30.

Friday, October 1, 2021

Covid 19: The Gift That Keeps On Giving

 United States Coronavirus Cases: 44,320,388 Deaths: 717,007

Chances are by 2022 the virus will become endemic and it will still kill off MAGAts but in smaller numbers. COVID will continue to cull the herd for years to come bringing the US to herd immunity. 

Variants will continue to show up worldwide and COVID spikes and dips are inevitable. There are pockets of MAGAts throughout Trumpistan where cases of COVID will surge. If a variant more virulent than the Delta variant were to emerge a death rate of 5% could be possible. 


COVID 19 hot spots will continue to erupt throughout Trumpistan for years to come. Currently the US is seeing a reported 1500 COVID deaths per day. The actual numbers are probably higher, especially in foul filthy Florida.

Related:

How to Deal with MAGAts. A MAGAt is a brain-dead admirer ...

https://medium.com/@whitfieldlarrabee/how-to-deal-with-magats-eea50d0af0e6

Aug 27, 2018 · A MAGAt is a brain-dead admirer of Donald Trump & his slogan, Make America Great Again. In dealing with MAGAts, it’s best to understand how they are formed. A large number of them have overdosed ...








Thursday, August 26, 2021

Foul Filthy Florida No Longer Reporting COVID 19 Cases and Deaths

 TAMPA (WFLA) – The Florida Department of Health plans to no longer release a daily COVID-19 report of state cases, deaths, and hospitalizations and will now issue a weekly report.



Most recently on Thursday, the Florida Department of Health reported 1,872 new cases, bringing the state’s overall total to 2,329,867 cases since the virus was first detected on March 1, 2020.

More than 10.3 million Floridians have been vaccinated – accounting for more than half of Florida’s eligible population with 85 percent of Florida’s seniors being vaccinated.

COVID-19 case and vaccine reporting will be available on a weekly basis at the state’s Florida Heath website every Friday.

Op Ed: This is good because now even more Filthy Floridians will die.

Democracies Worldwide Should Execute Trump Trolls and Putin Trolls

 Trump trolls and Putin trolls are committing espionage and therefore they can be treated as spies and executed under the law. When the spre...